Graft architecture

Yakushiji, T, Sakai, K., Kikuchi, A., Aoyagi, T, Sakurai, Y, and Okano, T. Graft architectural effects on thermo-responsive wettability changes of poly(A-isopropylacrylamidej-modified surfaces, Langmuire, 1998, 14, 4657-4662. 

Keywords Biomedical application Surface graft architecture... 

This article is intended to summarize new strategic and technological aspects of photoiniferter-based graft architectures in conjunction with biomedical applications as follows. 

Finally, biomedical applications aiming at controlled protein adsorption and cell adhesion on iniferter-driven surface graft architectures, by which a high-throughput screening of biocompatibility can be materialized, are presented. 

Scheme 1 Elemental reactions of DC chemistries used for design of controlled graft architecture...

Scheme 4 Hyperbranced multigeneration graft architecture based on sequential repeating process of copolymerization with chloromethyl styrene (CMS) as a comonomer and subsequent dithiocarbamation...

Fig. 10 Schematic drawing of the 1st generation (GI) to nth generation (Gn)-graft architectures...

Fig. 13 Hyperbranced graft architecture based on graft-on-graft technique, a Growing tree model (both stem and branch) b Growing hyperbranching model (controlled chain length) c Growing hyperbranching at stem end...

Fig. 15 a Hyperbranched block graft architecture, b Terminal endcapping via crossrecombination in the presence of DC substance... 

Because albumin, a major protein in blood, does not activate any body defense systems, an albuminated surface has a nonthrombogenic potential [3]. Surface graft architectures, in which albumin is covalently fixed at... 

Figure 35.7 Enzymatic extension of DNA-synthetic polymer hybrids and preparation of DNA-synthetic polymer graft architectures. (a) Schematic representation of enzymatic extension of ss DNA diblock copolymer using TDT and dNTP. P denotes the phosphate group(s) of the nucleotide ...

Figure 2.5 (a) Umbilical cord with central vein and smaller snrronnding arteries (left panel). This is clearly demonstrated on the microscopic view (right panel) (b) human umbilical cord vein manufactured as a vascular prosthesis including an outer Dacron mesh (c) retention of graft architecture with glutaraldehyde processing at 2 weeks, 8 months, and 2 years. 

Matsuda, T, Ohya, S., Photoiniferter-Based Thermoresponsive Graft Architecture with Albumin Covalently Fixed at Growing Graft Chain End, lanemuir 2005, 21, 9660-9665. 

---